CORAL GABLES, Fla., Aug. 29 /PRNewswire-FirstCall/ -- Catalyst
Pharmaceutical Partners, Inc. (Nasdaq: CPRX) a specialty pharmaceutical
company that acquires or in-licenses, develops and commercializes
prescription drugs for the treatment of drug addiction and obsessive
compulsive disorders, today announced that Patrick J. McEnany, President
and Chief Executive Officer, will be presenting an overview of the Company
at the Roth Capital Partners 2007 New York Conference on Wednesday,
September 5th at the Westin New York at Times Square hotel in New York
City. Mr. McEnany's presentation is scheduled for 1:00pm ET.
The presentation will be webcast live and can be accessed at
http://www.wsw.com/webcast/roth13/cprx/. An archived recording of the presentation
will be available for 90 days following the event.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of prescription
drugs for the treatment of addiction and obsessive compulsive disorders.
The Company has obtained from Brookhaven National Laboratory an exclusive
worldwide license for nine patents and four patents pending in the United
States relating to the right to use vigabatrin to treat a wide variety of
substance addictions and obsessive compulsive disorders. Catalyst has also
been granted rights to Brookhaven's vigabatrin-related foreign patents or
patents pending in more than 30 countries. The Company's initial product
candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast
Track" status by the U.S. Food & Drug Administration (FDA) for the
treatment of cocaine addiction. This indicates that the FDA has recognized
that CPP-109 is intended for the treatment of a serious or life-threatening
condition for which there is no effective treatment and which demonstrates
the potential to address unmet medical needs. Catalyst recently initiated a
180 patient randomized, double- blind, placebo-controlled, multi-center
U.S. Phase II clinical trial of CPP- 109 in patients with cocaine addiction
and expects to initiate a similar trial in patients with methamphetamine
addiction later this year.
For more information about the Company, go to http://www.catalystpharma.com.
This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may
cause the Company's actual results in future periods to differ materially
from forecasted results. A number of factors, including those factors
described in the Company's Annual Report on Form 10-K for 2006 and the
Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007
that the Company has filed with the U.S. Securities and Exchange Commission
("SEC"), could adversely affect the Company. Copies of the Company's
filings with the SEC are available from the SEC or may be obtained upon
request from the Company. The Company does not undertake any obligation to
update the information contained herein, which speaks only as of this date.
SOURCE Catalyst Pharmaceutical Partners, Inc.
 back to top
Related links:
http://www.catalystpharma.com
http://www.wsw.com/webcast/roth13/cprx
CONTACT:
Jack Weinstein, Chief Financial Officer of
Catalyst Pharmaceutical Partners, Inc., +1-201-934-4201,
jweinstein@catalystpharma.com; or Melody Carey of Rx
Communications Group, +1-917-322-2571, mcarey@rxir.com, for
Catalyst Pharmaceutical Partners, Inc.
|
